American Heart Association Initiative Aims to Accelerate Diagnosis adn Treatment for Aortic Stenosis
Table of Contents
A new programme focused on boosting clinical trial participation and improving diagnostic rates offers hope for individuals living with aortic stenosis, a frequently underdiagnosed heart condition.
People living with aortic stenosis (AS) may soon have faster access to cutting-edge care and treatment thanks to a new initiative launched by the American Heart Association. The effort is designed to significantly increase participation in vital clinical trials and expedite the diagnosis of this common, yet often overlooked, heart valve disease.
Did you know? – Aortic stenosis affects millions worldwide. The condition frequently enough goes unnoticed until symptoms become severe. Early detection and treatment are key to preventing serious complications and improving patient outcomes.
Understanding Aortic Stenosis
Aortic stenosis is characterized by the narrowing of the aortic valve, which restricts blood flow from the heart to the rest of the body. Left untreated, this condition can lead to severe complications, including heart failure and, ultimately, death. Early detection and intervention are crucial for improving patient outcomes.
Expanding Access to Clinical trials
The American Heart Association is expanding its support for patients with moderate AS by launching a new program to raise awareness of, and improve access to, clinical trials. This will be achieved through the Association’s extensive network of hospitals and specialized heart valve clinics nationwide.
Pro tip: – If you experience chest pain, shortness of breath, or fatigue, consult a doctor. Thes symptoms can indicate aortic stenosis. Early diagnosis and treatment can significantly improve your quality of life.
“Aortic stenosis is a serious condition, yet too often, people go undiagnosed until the disease progresses,” stated a senior official with the Association. “By identifying eligible participants for new clinical trials and supporting clinical research, this initiative will help shape the future of care for people affected by this disease.”
The initiative builds upon the existing infrastructure of the Association’s target: Aortic Stenosis™ program, which currently manages over 2,200 individuals with moderate AS through a quality advancement network. The expanded effort will engage at least 40 hospitals and their affiliated clinics,connecting more patients with research opportunities and promoting the development of innovative therapies.
Collaboration with Kardigan and Edwards Lifesciences
The program is supported by Kardigan, a company dedicated to revolutionizing cardiovascular disease treatment. According to a company release, kardigan’s mission is to move beyond simply managing symptoms and to redefine care for patients and their families, especially in areas where current therapies are limited.
Reader question: – What are your thoughts on the role of clinical trials in treating aortic stenosis? Share your viewpoint on the importance of research and innovation in improving patient care.
“Improving access to clinical trials will not only advance innovation, but also help more people recieve the diagnosis and treatment they need sooner,” said Jay Edelberg, M.D., Ph.D., co-founder and chief medical officer of Kardigan.
The Target: Aortic Stenosis™ program also receives support from Edwards Lifesciences.
addressing Barriers to Trial Enrollment
As part of this new effort, the American Heart Association will provide healthcare professionals with educational resources, quality improvement tools, and on-site support to help them better identify and refer eligible patients for clinical trials.A thorough survey will also be conducted to explore the challenges healthcare providers face in enrolling patients in structural heart disease research, with the goal of developing solutions to increase participation.
This multi-faceted approach underscores a commitment to accelerating
